January 6, 2015

DOTATATE PET/CT changed treatment plans for 60% of NET patients

PET/CT with Ga-68 DOTATATE has been found to change treatment plans in a majority of patients receiving initial evaluation and subsequent staging of neuroendocrine tumors (NETs), according to the results of two referring physician surveys published Dec. 11 in the Journal of Nuclear Medicine . {read more here}